Latest news
Jazz to buy Actio for up to $1.3B, gaining epilepsy asset - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 19:37:19 GMT$1.32 Billion for a Molecule: Jazz Pharmaceuticals Bets on Rare-Epilepsy Drug With No Approved Rivals - usaherald.comusaherald.com · Mon, 10 Aug 2026 19:01:18 GMTJazz Pharmaceuticals expands rare epilepsy pipeline with Actio Biosciences deal - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Mon, 10 Aug 2026 16:17:36 GMTJazz expands epilepsy portfolio with buy of Actio Biosciences - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 15:16:17 GMTJazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - ReutersReuters · Mon, 10 Aug 2026 15:11:12 GMTJazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 14:22:59 GMTJazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion - citybizcitybiz · Mon, 10 Aug 2026 13:11:44 GMTJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR NewswirePR Newswire · Mon, 10 Aug 2026 11:30:00 GMT